Dermatology

Psoriatic arthritis

Questions discussed in this category

How would you manage active severe psoriasis in a patient planning pregnancy, who also has psoriatic arthritis with well-controlled joint symptoms on certolizumab pegol (anti-TNF therapy)?

Patient is already on topical high potency corticosteroids. Any updated safety data on IL-17, IL-23 in pregnancy?

2 Answers available

How do you approach managing nausea and GI side effects when initiating methotrexate?

5 Answers available

What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Bissonnette et al., PMID 38324484

2 Answers available

Are there certain disease domains in a patient with psoriatic arthritis that will make bimekizumab a particularly good option?

For example, in patients with many swollen/tender joints, enthesitis, nail involvement do you expect particularly good response? Are there patients in...

2 Answers available

How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics?

3 Answers available

Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?

1 Answer available

Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?

3 Answers available

How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?

The patient has ongoing inflammatory arthritis despite methotrexate, apremilast, and jak inhibitor trials.

1 Answer available

How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?

What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?

2 Answers available

Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?

1 Answer available

Would you consider using a JAK inhibitor in combination with an IL 23 inhibitor in cases of severe psoriasis, psoriatic arthritis, or axial spondyloarthritis that is refractory to multiple biologic DMARDs?

2 Answers available

What is your approach to using apremilast for psoriatic arthritis in patients with history of depression?

1 Answer available

Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?

1 Answer available

Papers discussed in this category

The Journal of rheumatology, 2012-01

Combination biologic treatment of refractory psoriasis and psoriatic arthritis.

JAAD Case Rep, 2019 Oct 10

Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis.

Clinical rheumatology, 1988 Sep

Treatment of psoriatic arthritis with sulphasalazine: a one year open study.

Journal of the American Academy of Dermatology, 1987 Apr

Gold therapy and its indications in dermatology. A review.

Journal of the American Academy of Dermatology, 2020 May 19

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.

Annals of the rheumatic diseases, 2018-09

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Arthritis & rheumatology (Hoboken, N.J.), 2019-02

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.

RMD open, 2020 Feb

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.

Trials, 2022 Sep 05

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.

Annals of the rheumatic diseases, 2024 Mar 18

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.

Ann Rheum Dis, 2020 Dec 17

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.

Expert review of anticancer therapy, 2009-01

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Lancet Gastroenterol Hepatol, 2023 Feb 01

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.

The New England journal of medicine, 2024 Feb 08

An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.

Dermatology

Psoriatic arthritis

Questions discussed in this category

Papers discussed in this category

Related Topics in Dermatology